Biosite Triage ProfilER symptom panel
This article was originally published in The Gray Sheet
Executive Summary
Shipments of the "shortness-of-breath" test panel to distinguish among congestive heart failure, pulmonary embolism and heart attack will begin after the product debuts at the American Association for Clinical Chemistry annual meeting in Los Angeles July 25-29. Within 15 minutes, ER test-givers can measure five biomarkers: BNP, D-dimer, myoglobin, CK-MB and troponin I (1"The Gray Sheet" May 10, 2004, p. 23). The panel will "eliminate the need for the hospital to obtain multiple blood samples or employ one or more laboratory-based analyzers to accomplish multiple tests," Biosite states in a June 30 release announcing 510(k) clearance. The San Diego firm is emphasizing the assay's potential to combat "overcrowding" in emergency departments...
You may also be interested in...
Cardiac Markers Clash For Hospital, Lab Space: Biosite Triages R&D Projects
Biosite's pursuit of additional disease markers for its Triage immunoassay meter will continue unabated this summer, even as the company defends BNP test market share from newcomer Abbott Labs and imminent rival Dade Behring
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.